Advancing Fusion’s Targeted 225 Ac Platform- A Glimpse at What’s Clinically Advancing & What’s to Follow post the Astra Zeneca Acquisition
Time: 9:00 am
day: Conference Day One
Details:
- Outlining why 225Ac remains an attractive radioisotope for targeted therapy
- Uncovering strategies for antibody-based radiotherapy
- Navigating clinical strategy and updates on Fusion’s antibody and small molecule programs, including FPI-2265 (phase 2/3 study)
